Nvidia’s Q3 FY27: The Reassurance Before the Storm
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
@evfcfaddict @alluvialcapital $BWEL will work eventually
Tom likes the stock. $MKL adding >10% buyback auth, now ~15% buyback auth outstanding.
Target Posts Strongest Sales Growth in Years as Focus on New Products, Value Pays Off $TGT
TJX Raises Full-Year Outlook, Expects Sales Trends to Accelerate Through Holiday Season $TJX
Cal-Maine Foods to Cull 1.76 Million Birds After Florida Facility Tests Positive for Bird Flu $CALM
Nvidia faced China workaround enforcement concerns as technology fell 6%; energy rose 4.5%, while the company raised eFY28 revenue growth…
MiniMed's 15.8% Q1 organic growth and 20% U.S. pump-volume increase support a product-cycle recovery as split-off selling fades.
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and guided $130 billion, while Jensen Huang’s resignation left Colette Kress as…
Pfizer’s Q3 revenue reached $16.58 billion, launched and acquired products grew 32%, and FY26 guidance rose to $62 billion to $64 billion.
NVIDIA’s fiscal third-quarter 2027 results are its first earnings report since Jensen Huang’s resignation as CEO.
UFP Industries trades near its 2022 price despite EPS falling 62%; a $95–$105 valuation assumes $6.30 normal-year EPS, with freight and…
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and raised its fiscal 2028 growth outlook to 75% as interim CEO Colette Kress…
Century Aluminum (CENX) could benefit from U.S. tariffs, Midwest aluminum premiums and constrained global supply, with the stock trading…
Figma grew Q3 revenue 43% to $391.4 million, raised FY2026 guidance to nearly $1.5 billion and guided Q4 above consensus despite the stock…
Nvidia raised its fiscal 2028 growth outlook, but shares reversed as investors focused on uncertainty beyond January 2028.
ZTS · long Zoetis, the animal prescription-medicines company, is presented as a long investment despite concerns around its 2026 and 2027 outlook.
Meta grew first-quarter revenue 33% as AI lifted engagement and ad conversion, while data-center depreciation cut margins and personalized…
GPGI, formerly CompoSecure, is David Cote’s $4.2 billion industrial acquisition platform, managed by Resolute Holdings for 2.5% of adjusted…
SharkNinja, spun off from Hong Kong-listed JS Global Lifestyle and listed at $42.31 in July 2023, is pitched as a 40% upside compounder.
Ulta Beauty’s 46 million-member loyalty model drove strong historical cash flow, but earnings have stalled since fiscal 2022 as SG&A rose;…
Americold and Lineage face a cold-storage supply overhang, weakening rents and labor and power costs that pressure thin NOI margins and…
Apple’s Kalshi earnings-call contracts price mentions of “foldable” and “glasses,” while its 24-year transcript record indicates management…
GCI Liberty is acquiring Alaska’s Quintillion fiber network for $360 million, giving John Malone a platform to expand GLIBK beyond its…
RE/MAX’s $13.80-per-share Real Brokerage offer is capped at $80 million cash, implying roughly $11.40 of value at REAX’s $2.02 share price.
Insperity's healthcare-cost spike, $120 million technology expense and weak SMB hiring drove its 70% drawdown; normalized earnings could…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.